Alaskan Husky Cone Degeneration: What Sled Dog DNA Studies Show

SamSomeone at a race said Alaskan Huskies can carry a day-blindness gene. Is that real?

Elena MarshYes. A 2013 BMC Genetics study confirmed the mutation in sled dogs at the DNA level. What it means for your own yard is a different, more interesting question.

SamMy dogs aren’t registered anywhere. Does the research even apply to them?

Elena MarshIt does. Researchers studied Alaskan sled dogs as a working population, not a breed. The catch is that the samples are small, and the study authors say so themselves.

SamSo should I be testing every dog, or is this a once-in-a-lifetime problem?

Elena MarshThat depends on your lines. The published carriers clustered in one family line, which changes how a kennel owner should spend money on testing.

Bottom line: The CNGB3 deletion that causes cone degeneration (day blindness) has been confirmed in Alaskan sled dogs, but only as carriers: Yeh et al. (2013) found 3 carriers among 38 unrelated sled dogs, and all three came from the distance-racing subgroup and shared an ancestor four and five generations back. No affected Alaskan Husky has been reported in the published literature we could find, and a later panel of 346 sled dogs did not list cone degeneration among the conditions it found. Read that as a kennel-and-lineage question, not a breed-wide rate. Embark names “Alaskan-type Husky” for this variant and UC Davis VGL lists “Alaskan Sled Dog”; OFA accepts results from unregistered dogs. A DNA result is risk information, not a diagnosis. If a pup squints and stumbles in sunlight, the confirming test is an electroretinogram (ERG) arranged through your veterinarian and a board-certified ophthalmologist. There is no approved treatment.

What a 38-dog screen of Alaskan sled dogs actually measured

SamThree out of thirty-eight sounds like a lot. Is that the carrier rate for Alaskan Huskies?

Elena MarshNo. Yeh and colleagues wrote that many more sled dogs would be needed for a frequency estimate, and all three carriers were related through one distance line.

The 2013 study by Yeh, Komáromy and colleagues in BMC Genetics asked a narrow question: where else is the Malamute-type CNGB3 deletion hiding? They screened pooled DNA from several breeds, choosing dogs within each group that shared no grandparents, so that one big family would not dominate the result.

The sled dog sample was 38 dogs: 23 sprint dogs and 15 distance dogs. The paper describes Alaskan sled dogs as “mixed breed dogs comprised of several different lineages” that split genetically into sprint and distance clusters, drawing on the earlier ancestry work by Huson et al. (2010).

Three sled dogs carried one deleted copy: “All three sled dogs were from a subgroup of distance runners and did share a common ancestor four and five generations back”. When they sequenced across the deletion, the breakpoints matched those in the Malamute, the Miniature Australian Shepherd and a carrier Siberian Husky. This is one ancestral chromosome, identical by descent, not a new mutation.

Because both the Alaskan Malamute and the Siberian Husky appear in sled-dog ancestry, they wrote that the allele “could have been contributed by either breed”. They also wrote that they were “not aware of any reports about day-blindness in these arctic breeds”, adding that its occurrence “would not be surprising” given the findings.

So the allele is confirmed in the working population, it was concentrated in one related group, and no affected sled dog has been published. What the data cannot support is a population percentage: the sample was small and pooled, and the authors declined to estimate a frequency.

The condition itself fits in a paragraph. CNGB3 encodes the beta subunit of a channel that cone photoreceptors need to respond to light. Two canine variants are known: the large deletion first found in Alaskan Malamute-derived dogs (about 405 kb, also removing parts of neighboring genes) and an exon 6 point mutation (D262N) found in German Shorthaired Pointers (Sidjanin et al., 2002). Inheritance is autosomal recessive. Affected pups lose daylight vision and become light-sensitive at roughly 8 to 12 weeks while dim-light vision is preserved; the fundus looks normal (a 2024 review notes no fundus changes even up to at least four years of age), so confirmation needs ERG. Names vary: cone degeneration (cd), day blindness, hemeralopia, achromatopsia and, in the 2024 nomenclature reflected in OMIA, ACH-CNGB3. OMIA’s breed list for this entry includes the Alaskan Husky.

Why 346 sled dogs later turned up no cone degeneration, and what that does not prove

Eight years later came a larger dataset. Thorsrud and Huson (2021) analyzed commercial Embark results from 346 Alaskan sled dogs, 13 Polar Huskies and 89 Siberian Huskies drawn from 61 kennels. Of the 346 Alaskan sled dogs, 208 were competitive sprint dogs.

Embark’s panel covered more than 190 conditions at the time, and the authors state that every dog was tested for the full list regardless of ancestry. Only seven health traits were found in the sledding dogs: ALT activity, Alaskan husky encephalopathy, Collie eye anomaly, degenerative myelopathy, dilated cardiomyopathy, factor VII deficiency and ichthyosis. Cone degeneration was not among them.

Writing “zero carriers in 346 dogs” would overstate the paper. The text does not confirm whether the CNGB3 deletion was on Embark’s panel at the time of those tests, and the authors describe their sample as an opportunistic dataset of limited size. What can be said is narrower: cone degeneration was not among the conditions the study reported.

Still, the two studies fit together. An allele sitting in one distance line can be missed by a sample that leans sprint: 208 of the 346 dogs in 2021 were sprint dogs, while all three 2013 carriers were distance dogs. That does not prove sprint lines are free of it. It does suggest that the useful unit for thinking about risk is the lineage behind your dogs, not the label “Alaskan Husky”. The most common ancestry call in those sled dogs was Embark’s “Supermutt” category, a reminder of how mixed a modern racing dog’s heritage is.

A kennel, not a breed: reading results inside a working yard

SamIf it runs in families, should I only test the dogs I plan to breed?

Elena MarshBreeding stock first. Carriers look normal, and the UC Davis VGL result key says two carriers are predicted to produce 25% affected pups. Testing pups only tells you afterwards.

Recessive genetics behaves the same whether a dog has papers or not. In UC Davis VGL’s result key, N/N dogs will not develop these forms of cone degeneration, and N/CD1 or N/CD2 dogs are carriers that pass a variant to about half of their offspring. The laboratory also treats a dog carrying one copy of each variant (CD1/CD2, a compound heterozygote) as affected. That last point is the laboratory’s interpretive rule; we could not find a published canine case report that documents a compound heterozygote.

What changes in a sled-dog yard is the structure of the population around the test:

• Lines move as units. In a population bred kennel by kennel rather than through a closed stud book, a widely used sire that carries the deletion can pass it into many yards at once. Shared ancestry four and five generations back is exactly the pattern the 2013 carriers showed.
• Outcrosses can import it. The deletion is shared by descent with the Alaskan Malamute and Siberian Husky, so recent outcrosses to either are worth noting. In Donner et al. (2023), the deletion’s allele frequency was 0.00496 among 504 genetically purebred Malamutes and 0.000111 among 9,035 Siberian Huskies. Those are breed figures, not estimates for Alaskan Huskies, which the paper’s breed table does not include.
• Affected dogs can appear outside any recognized breed. In that 1,054,293-dog commercial dataset, all six dogs carrying two copies of the deletion were classified as mixed breed by genetic testing, and none of the 242,661 genetically purebred dogs had two copies. The paper does not analyze why or identify those dogs as sled dogs; the lesson is simply that “no breed registry” does not mean “no risk”.

A sensible kennel plan: test breeding candidates once (the genotype never changes), record the result against the dog’s microchip, ask for results on any outside sire before a breeding, and avoid carrier-to-carrier pairings rather than culling carriers outright. For this CNGB3 deletion specifically, a carrier bred to a tested-clear mate produces no pups with two copies, though about half the litter will carry; it says nothing about other eye conditions.

Which tests actually name your dog, and what they cost

The test you buy should explicitly cover the Malamute-type deletion. Three providers do, and two name sled dogs in their own wording.

Embark lists “Alaskan-type Husky” among six affected breed entries for the deletion, states there is “currently no treatment”, and asks owners to consult a veterinarian about eyesight even if a dog tests clear. It does not explain how a dog is assigned to that category, so treat the label as a company classification, not a research definition.

UC Davis VGL suits a kennel: a single-purpose test with a multi-dog discount. It mails cheek-and-gum brushes (usually three per dog), recommends waiting until puppies are at least three weeks old, listed turnaround as at least 15 business days, and can forward results to OFA. Its live page was unreachable in October 2026, so confirm the September 2025 price before ordering. One caution: the VGL page says the CD2 point variant also occurs in Alaskan Sled Dogs, but neither the references it cites nor our own literature search turned up a published source for that claim.

Wisdom Panel covers the deletion in its health-inclusive kits (such as Premium) and reports that it is “Found in 1 in 5,000 dogs in our testing”. The page does not say whether that counts one copy or two, so it should not be compared directly with research figures. Its US checkout offers four interest-free payments of USD 31.99 on the Premium kit.

One trap is specific to anyone browsing European catalogues: LABOKLIN’s test 8780, sold under the name “Cone Degeneration (CD)”, is assigned to the German Shorthaired Pointer and examines that breed’s point mutation, not the deletion found in sled dogs. A clear result from that assay says nothing about the Malamute-type allele.

Race rules check hearts and blood, not genes

SamDoesn’t the Iditarod vet check catch problems like this before a dog races?

Elena MarshThe 2027 Iditarod rules require a physical exam, bloodwork and an ECG for every dog, but no DNA test. Nothing in that screen is designed to find a carrier.

The Iditarod’s 2027 rulebook is the most detailed public statement of what a long-distance race demands of a dog. Rule 40 requires that “every dog must undergo health examination with a physical exam and history review (including proof of required vaccinations, dewormer, and microchipping), and health screening testing in the form of bloodwork and ECGs (EKGs)”. Conditions that bar a dog include seizures, fainting, pregnancy and poor body condition, and the Chief Veterinarian may deny entry to any dog with an abnormality that predisposes it to serious injury or death.

Rule 43 is the only line that describes the dogs themselves: “Only dogs suitable for arctic travel will be permitted to enter the race”. Race officials decide suitability; there is no breed or registry requirement.

The genetics clause sits in a different document. Every entrant signs the 2027 Kennel Standards Agreement, which adopts the Mush with P.R.I.D.E. 2019 kennel standards. Under “Breeding” it reads: “Records of breeding status are kept on all dogs. Dogs with genetic defects/diseases are prevented from breeding”. Compliance is by self-certification; the race committee “will not independently inspect except for cause or reasonable suspicion”.

Side by side, the two documents leave a gap. The breeding clause addresses dogs with a genetic disease, but for a recessive condition the dogs that keep the allele circulating are healthy carriers, and no race document asks anyone to identify them. The rules are built around race safety, so screening for this condition is entirely a kennel decision.

Day blindness also creates a practical risk in a working dog: one that sees well at night but poorly in snow glare may look slow or “unwilling” on daylight runs. A study of an obstacle course by Garcia et al. (2010) found that achromatopsic dogs took 2.6 times as long to cross at 25 lux, 3.2 times at 65 lux and 5.7 times at 646 lux, compared with the same dogs in near darkness (0.2 lux), and the method distinguished affected dogs at light levels of 25 lux and above. If a young dog performs well on night runs and falls apart in sunshine, it is worth a veterinary conversation before anyone labels it a poor worker.

The other big northern race is in flux: the Anchorage Daily News reported in January 2026 that the Canadian Yukon Quest would not run that year for lack of an active organizing board, while Yukon Quest Alaska launched a 750-mile race from Fairbanks.

No registry, one open database: paperwork in the US, Canada and the UK

An Alaskan Husky sits outside every major pedigree system. The AKC has no breed page for it; its route for such dogs is AKC Canine Partners, a program the AKC says “welcomes all mixed-breed dogs” for companion events such as Canine Good Citizen, agility and rally. The Canadian Kennel Club’s breed list includes the Alaskan Malamute, the Siberian Husky and the Canadian Eskimo Dog, but not the Alaskan Husky. In the UK, the Royal Kennel Club’s Health Test Results Finder covers dogs on its Breed Register, so an unregistered sled dog has no RKC record route.

That leaves the Orthopedic Foundation for Animals as the one public database that will take the result. OFA’s FAQ is explicit: “The OFA does not require dogs to be purebred or registered in order to perform an OFA evaluation or to register test results into our databases”. Its fee schedule lists USD 15 to register a DNA test result (with litter and kennel rates available), and USD 15 for the eye registry. For a kennel that sells pups or stands a stud, that is the closest thing to a verifiable certificate this population has.

Outside the US, practicalities differ:

• Canada: Embark charges a flat USD 20 per order to ship outside the US, and its prepaid return label does not work abroad, so you pay postage to return the swab. We found no Canadian-dollar price for this test from these providers, so budget in US dollars plus shipping.
• United Kingdom: Wisdom Panel sells Premium at GBP 144.99 regular, GBP 108.74 on sale (October 4, 2026), and its UK site carries the same Malamute-type condition page.

Insurance is where timing dominates. In the US, Figo lists “Hereditary and Congenital Disorders” as covered and says it may cover “curable” pre-existing conditions after 12 symptom-free months. Cone degeneration is not curable, so that pathway would not reopen coverage once signs have been noted. In Canada, Pets Plus Us lists hereditary conditions as covered with “no breed exclusions”, but defines a pre-existing condition as one that “showed itself, although it may not have been diagnosed, before coverage was effective”, and applies a 14-day illness waiting period. Its accident-and-illness plans offer CAD 7,500 or CAD 15,000 in annual coverage, with an age-based deductible you choose (CAD 100, 200 or 300 for dogs up to five years old). The practical rule: enroll a pup before any light sensitivity is noticed.

From a squinting pup to an ERG: the veterinary route

SamMy vet looked in a pup’s eyes and said they look normal. Can it still have this?

Elena MarshYes. A 2024 review by Dufour and Aguirre reports no fundus changes in affected dogs even at four years of age. Confirmation requires an electroretinogram.

Embark’s condition page lists repeated blinking in daylight, head shaking, seeking out dimmer areas, and puppies bumping into objects that littermates avoid. Signs begin around 8 to 12 weeks. In a sled-dog yard, the tell is often the contrast between a pup that moves confidently at dusk and one that freezes or hesitates in bright snow at midday.

Start with your regular veterinarian, who can rule out common causes of squinting and decide on referral. The definitive test is electroretinography, which records the retina’s electrical response to light and shows lost cone responses with preserved rod responses. ERG is typically done by a board-certified veterinary ophthalmologist. The American College of Veterinary Ophthalmologists runs a public “Locate an Ophthalmologist” search. Not every specialty practice runs ERG, so ask when booking; university teaching hospitals such as Cornell’s Ophthalmology Service list electroretinography among their diagnostics. Bring the DNA report, the dog’s age at first signs and, if possible, notes on how it behaves at different times of day.

Two cautions keep the DNA test in its place:

• A clear CNGB3 result does not rule out day blindness. In Malamutes, Seddon et al. (2006) reported genetic heterogeneity in an Australian family, and Yeh et al. note a day-blind Malamute that tested normal for the deletion. In Gordon Setters with a day-blindness picture, CNGB3 mutations were not detected (Good et al., 2016); in Standard Wire-haired Dachshunds, CNGB3 and nine other candidate genes were excluded (Wiik et al., 2008). German Shepherd and Labrador achromatopsia involves a different gene, CNGA3.
• Not every early day-blind dog has a stationary condition. The review by Dufour and Aguirre describes very early-onset day blindness from an NPHP5 variant in American Pit Bull Terriers, in which rod responses are also lost. A specialist’s ERG distinguishes these patterns; a cheek swab cannot.

For a confirmed dog, the reported course is loss of daylight vision with dim-light vision preserved, which differs from progressive retinal atrophy. Management is environmental: shift work and exercise toward dawn and dusk, provide shade, and consider tinted dog goggles if bright light is uncomfortable. These measures ease symptoms; they are not treatment. Whether an affected dog can safely work in a team in daylight is a judgment for your veterinarian and you, not a DNA result.

What worked in dogs and stalled in people: the treatment research

Canine CNGB3 achromatopsia became a key gene therapy model because roughly half of human achromatopsia also involves CNGB3: Kohl et al. (2005) found CNGB3 mutations in 163 of 341 patients.

In research colony dogs, Komáromy et al. (2010) used an AAV vector carrying human CNGB3 to restore cone function and day vision in both canine models, the deletion and the point mutation. The effect was mutation independent but depended on promoter and age, and in younger animals it remained stable for at least 33 months. Older dogs responded poorly: a follow-up study (Komáromy et al., 2013) found treatment effective under six months of age but minimally effective after one year. Pre-treating with ciliary neurotrophic factor (CNTF), which temporarily “deconstructs” photoreceptors, then rescued cone function in all mutant dogs treated between 14 and 42 months of age. Safety work for a human trial (Ye et al., 2017) found focal chorioretinitis at high doses.

The human side has been sobering. A five-person trial of a CNTF implant (Zein et al., 2014) found no measurable improvement in cone function over one year and concluded that it revealed “a species difference between human and canine CNGB3 cones in response to CNTF”. A first-in-human AAV8 gene therapy trial in 23 adults and children (Michaelides et al., 2023) found acceptable safety overall, with intraocular inflammation in 9 participants, but “no consistent pattern of change” in efficacy measures at 24 weeks, though some individuals reported improvements. Reviewing the gap, Dufour and Aguirre (2024) note that the promoter used in the human trial was not the one that worked best in dogs, and that the CNTF strategy that rescued older dogs was ineffective in patients. A 2024 review (Baxter and Borchert) states there is no FDA-approved treatment for human achromatopsia.

For an Alaskan Husky owner, the takeaway is direct: no gene therapy or CNTF treatment is available for pet or working dogs. Informed breeding and sensible management of an affected dog are the tools that exist today.

Frequently asked questions

Q. What percentage of Alaskan Huskies carry the cone degeneration deletion?
Nobody knows. The only molecular screen found 3 carriers among 38 sled dogs, all from one distance-racing subgroup with a shared ancestor, and its authors said many more dogs would be needed for an estimate. Do not apply Malamute or Siberian Husky frequencies to Alaskan Huskies.

Q. Has an Alaskan Husky ever been diagnosed with cone degeneration?
No affected Alaskan Husky has been reported in the published literature we reviewed. The 2013 authors wrote that a case would not be surprising given the carriers they found.

Q. My dog is unregistered. Can I still record a result publicly?
Yes. OFA states that it does not require dogs to be purebred or registered to enter test results in its databases. The fee to register a DNA result is listed as USD 15 per test.

Q. Does the Iditarod require a DNA test for cone degeneration?
No. The 2027 rules require a physical exam, bloodwork and an ECG for each dog. The Kennel Standards Agreement says dogs with genetic defects or diseases are prevented from breeding, but it does not require genetic testing or address carriers.

Q. Which test should I order for a sled dog?
Choose one that covers the Alaskan Malamute-type CNGB3 deletion. UC Davis VGL tests both known variants and lists Alaskan Sled Dog as appropriate; Embark lists “Alaskan-type Husky” for the deletion. A test built only for the German Shorthaired Pointer point mutation will not detect it.

Q. My dog tested clear but avoids bright light. What now?
See your veterinarian. A clear result only covers this gene; day blindness has other genetic and non-genetic causes. Diagnosis requires an eye examination and, if indicated, an ERG by a veterinary ophthalmologist.

Q. Is there a cure?
No. Gene therapy restored cone function in research dogs, but it is not available for pets or working dogs, and the CNGB3 human trial has not shown consistent benefit. Management focuses on reducing bright-light exposure.

References

• Yeh CY, Goldstein O, Kukekova AV, Holley D, Knollinger AM, Huson HJ, Pearce-Kelling SE, Acland GM, Komáromy AM (2013). Genomic deletion of CNGB3 is identical by descent in multiple canine breeds and causes achromatopsia. BMC Genetics 14:27.
• Thorsrud JA, Huson HJ (2021). Description of breed ancestry and genetic health traits in arctic sled dog breeds. Canine Medicine and Genetics 8:8.
• Huson HJ, Parker HG, Runstadler J, Ostrander EA (2010). A genetic dissection of breed composition and performance enhancement in the Alaskan sled dog. BMC Genetics 11:71.
• Donner J, Freyer J, Davison S, Anderson H, Blades M, Honkanen L, Inman L, Brookhart-Knox CA, Louviere A, Forman OP, Chodroff Foran R (2023). Genetic prevalence and clinical relevance of canine Mendelian disease variants in over one million dogs. PLoS Genetics 19(2):e1010651.
• Sidjanin DJ, Lowe JK, McElwee JL, Milne BS, Phippen TM, Sargan DR, Aguirre GD, Acland GM, Ostrander EA (2002). Canine CNGB3 mutations establish cone degeneration as orthologous to the human achromatopsia locus ACHM3. Human Molecular Genetics 11(16):1823-1833.
• Seddon JM, Hampson EC, Smith RI, Hughes IP (2006). Genetic heterogeneity of day blindness in Alaskan Malamutes. Animal Genetics 37(4):407-410.
• Garcia MM, Ying GS, Cocores CA, Tanaka JC, Komáromy AM (2010). Evaluation of a behavioral method for objective vision testing and identification of achromatopsia in dogs. American Journal of Veterinary Research 71(1):97-102.
• Good KL, Komáromy AM, Kass PH, Ofri R (2016). Novel retinopathy in related Gordon setters: a clinical, behavioral, electrophysiological, and genetic investigation. Veterinary Ophthalmology 19(5):398-408.
• Wiik AC, Ropstad EO, Bjerkås E, Lingaas F (2008). A study of candidate genes for day blindness in the standard wire haired dachshund. BMC Veterinary Research 4:23.
• Tanaka N, Dutrow EV, Miyadera K, Delemotte L, MacDermaid CM, Reinstein SL, et al. (2015). Canine CNGA3 gene mutations provide novel insights into human achromatopsia-associated channelopathies and treatment. PLoS One 10(9):e0138943.
• Komáromy AM, Alexander JJ, Rowlan JS, Garcia MM, Chiodo VA, Kaya A, Tanaka JC, Acland GM, Hauswirth WW, Aguirre GD (2010). Gene therapy rescues cone function in congenital achromatopsia. Human Molecular Genetics 19(13):2581-2593.
• Komáromy AM, Rowlan JS, Corr AT, Reinstein SL, Boye SL, Cooper AE, Gonzalez A, Levy B, Wen R, Hauswirth WW, Beltran WA, Aguirre GD (2013). Transient photoreceptor deconstruction by CNTF enhances rAAV-mediated cone functional rescue in late stage CNGB3-achromatopsia. Molecular Therapy 21(6):1131-1141.
• Ye GJ, Komáromy AM, Zeiss C, Calcedo R, Harman CD, Koehl KL, Stewart GA, Iwabe S, Chiodo VA, Hauswirth WW, Aguirre GD, Chulay JD (2017). Safety and efficacy of AAV5 vectors expressing human or canine CNGB3 in CNGB3-mutant dogs. Human Gene Therapy Clinical Development 28(4):197-207.
• Zein WM, Jeffrey BG, Wiley HE, Turriff AE, Tumminia SJ, Tao W, Bush RA, Marangoni D, Wen R, Wei LL, Sieving PA (2014). CNGB3-achromatopsia clinical trial with CNTF: diminished rod pathway responses with no evidence of improvement in cone function. Investigative Ophthalmology & Visual Science 55(10):6301-6308.
• Michaelides M, Hirji N, Wong SC, Besirli CG, Zaman S, Kumaran N, et al. (2023). First-in-human gene therapy trial of AAV8-hCARp.hCNGB3 in adults and children with CNGB3-associated achromatopsia. American Journal of Ophthalmology 253:243-251.
• Dufour VL, Aguirre GD (2025; online 2024). Canine models of inherited retinal diseases: from neglect to well-recognized translational value. Mammalian Genome 36(2):500-510.
• Baxter MF, Borchert GA (2024). Gene therapy for achromatopsia. International Journal of Molecular Sciences 25(17):9739.
• Kohl S, Varsanyi B, Antunes GA, Baumann B, Hoyng CB, Jägle H, et al. (2005). CNGB3 mutations account for 50% of all cases with autosomal recessive achromatopsia. European Journal of Human Genetics 13(3):302-308.
• Online Mendelian Inheritance in Animals (OMIA). OMIA:001365-9615 — Achromatopsia-3, CNGB3-related in Canis lupus familiaris. Nicholas FW, Tammen I, Sydney Informatics Hub (2025). doi:10.25910/2AMR-PV70
• University of California, Davis, Veterinary Genetics Laboratory. Cone Degeneration (dog DNA test). Wayback Machine snapshot 2025-09-11.
• Wisdom Panel (Mars/Kinship). Cone Degeneration (Discovered in the Alaskan Malamute) — dog health condition page (en-gb). Accessed 2026-10-04.
• LABOKLIN (UK). Cone Degeneration (CD), test number 8780 / LABOGEN. Cone Degeneration (CD). Accessed 2026-10-04.
• Iditarod Trail Committee. Iditarod Trail International Sled Dog Race Official Rules 2027. Accessed 2026-10-04.
• Iditarod Trail Committee. 2027 Kennel Standards Agreement. Accessed 2026-10-04.
• Orthopedic Foundation for Animals. Our Fees. Accessed 2026-10-04.
• Pets Plus Us. Accident and Illness Coverage. Accessed 2026-10-04.

About the author

Elena Marsh

Editor & writer (not a veterinarian)

A writer with a molecular-biology background and a lifelong dog and cat owner. Not a veterinarian — she translates peer-reviewed genetics research and primary data into plain language, always as information rather than diagnosis.